Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Using Steroids to Manage Immunotherapy-Associated AEs in Melanoma

March 30th 2020

Kathleen Madden, FNP, MSN, AOCNP, APHN, discusses how to judiciously use steroids to manage adverse events in patients with melanoma who are receiving immunotherapy.

Dr. Polsky on the Clinical Validity of ctDNA in BRAF-Mutant Melanoma

March 23rd 2020

David Polsky, MD, PhD, discusses the use of circulating tumor DNA (ctDNA) in the COMBI-d trial on melanoma.

John Theurer Cancer Center Evaluating Personalized Cancer Vaccine in High-Risk Melanoma

March 4th 2020

An ongoing clinical trial will assess whether the adjuvant combination of the personalized cancer vaccine mRNA-4157 and pembrolizumab improves recurrence-free survival compared with pembrolizumab alone in patients with complete resection of cutaneous melanoma and a high-risk of recurrence.

Dr. Liebman on the Use of Digital Surveillance in Melanoma

February 28th 2020

Tracey Liebman, MD, discusses the use of digital surveillance in melanoma.

Dr. Shapiro on the Surgical Management of Advanced-Stage Melanoma

February 28th 2020

Richard L. Shapiro, MD, discusses the surgical management of advanced-stage melanoma.

Dr. Weber on Emerging Immunotherapy Combinations in Melanoma

February 19th 2020

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the melanoma program, Laura and Isaac Perlmutter Professor of Oncology, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses emerging immunotherapy combinations in melanoma.

Adjuvant Ipilimumab Improves OS in High-Risk Melanoma

February 18th 2020

Adjuvant treatment with ipilimumab, when given at a 3-mg/kg dose, was found to improve overall survival compared with high-dose interferon alfa in patients with high-risk melanoma.

Nuances of Immunotherapy-Related AEs in Melanoma

February 14th 2020

Kathleen Madden, FNP, MSN, AOCNP, APHN, discusses the nuances of immunotherapy related adverse events in melanoma.

Jeffrey Weber, MD, PhD: Charting New Territories in Melanoma

February 12th 2020

In our exclusive interview, Jeffrey S. Weber, MD, PhD, shares with us his journey into the melanoma field and the lessons he has learned along the way, some of the key studies that have significantly impacted his career and clinical practice, and what lies ahead in the melanoma pipeline.

CTC Detection Linked to Relapse in Stage III Melanoma

February 12th 2020

The presence of circulating tumor cell was found to be independently associated with relapse in patients with stage III melanoma, suggesting that CTC assessment may be useful in identify patients who are at risk for relapse and could benefit from adjuvant therapy.

ASCO Names Refinement of Surgical Treatment of Cancer as Advance of the Year

February 5th 2020

Following significant progress made in the development of novel systemic therapies for patients with cancer, the role of surgery in oncology continues to evolve. To this end, ASCO has selected the refinement of surgical treatment of cancer as its Advance of the Year.

Experts Share What They're Going to Work on Improving in Practice This Year

February 1st 2020

OncLive interviewed experts at the State of the Science Summits™ in January 2020 on what they are going to work on improving in clinical practice this year.

Dr. Liebman on Toxicities of BRAF Inhibitors in Melanoma

January 31st 2020

Tracey Liebman, MD, discusses the toxicities associated with BRAF inhibitors in melanoma.

Investigators Tackle Resistance, Poor Response in Metastatic Melanoma

January 31st 2020

Immune checkpoint inhibitors (ICIs) combined with the anti–CTLA-4 agent ipilimumab (Yervoy) have dramatically improved survival in metastatic melanoma, but resistance and lack of response remain obstacles to wider efficacy, Mario Sznol, MD, said in a presentation during the 4th Annual International Congress on Immunotherapies in Cancer®. Multiple efforts are under way to understand these issues better and develop improved biomarkers for response, Sznol added.

Surgical Resection Now Individualized Approach in Modern Melanoma Paradigm

January 28th 2020

Richard L. Shapiro, MD, discusses the evolution and current role of surgery in advanced melanoma.

Dr. Weber on Adjuvant Approaches in Stage III Melanoma

January 27th 2020

Jeffrey S. Weber, MD, PhD, discusses adjuvant approaches in stage III melanoma.

Dr. Pavlick on Importance of Immunotherapy in Metastatic Melanoma

January 27th 2020

Anna C. Pavlick, DO, discusses the importance of immunotherapy for patients with metastatic melanoma.

Treatment-Related Dermatologic AEs in Melanoma Require Careful Management

January 24th 2020

Tracey Liebman, MD, discusses the identification and management of treatment-related dermatologic AEs in patients with melanoma.

Targeting the Hedgehog Pathway Holds Promises and Pitfalls

January 18th 2020

Although small molecule inhibitors of the Hedgehog signaling pathway have transformed the treatment paradigm for advanced basal cell carcinoma, the most common form of skin cancer, efforts to expand their use to other tumor types have proved elusive.

Optimal AE Management Required With Immunotherapy in Melanoma

January 17th 2020

Kathleen Madden, FNP, MSN, AOCNP, APHN, discusses optimal management of adverse events associated with various therapies for patients with melanoma.